Aurinia Pharmaceuticals (AUPH) AI Stock Analysis

• Market Cap: $1.70B
• Dividend Yield: N/A
• Average Volume (3M): 1.72M
• Price to Earnings (P/E): 30.1
• Beta (1Y): 0.76
• Revenue Growth: 25.59%
• EPS Growth: N/A
• Country: US
• Employees: 130
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.16
• Shares Outstanding: 131,629,550
• 10 Day Avg. Volume: 1,663,623
• 30 Day Avg. Volume: 1,718,570
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.55
• Enterprise Value/Revenue: 3.58
• Enterprise Value/Gross Profit: 4.00
• Enterprise Value/Ebitda: 10.77
• 1Y Price Target: $12.00
• Price Target Upside: -6.61% Downside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 79 Outperform
• Price Target: $14.00 ▲(8.95% Upside)

Aurinia Pharmaceuticals' strong financial performance and positive earnings call are the most significant factors contributing to the stock's score. The company's revenue growth, improved profitability, and increased guidance are key strengths. However, the high valuation and overbought technical indicators present potential risks. The decrease in cash and investments due to share repurchases is a secondary concern.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for LUPKYNIS and effective market penetration, enhancing long-term business sustainability.

Cash Flow Management

Positive cash flow from operations demonstrates improved financial health and operational efficiency, supporting future growth initiatives.

Clinical Development

Successful clinical trials for new products like aritinercept can expand Aurinia's product pipeline, driving long-term growth and market diversification.

Negative Factors

Cash and Investments Decrease

The decrease in cash and investments may limit financial flexibility and ability to invest in growth opportunities, impacting long-term strategic initiatives.

Share Repurchase Impact

Significant share repurchases reduce available cash, potentially constraining investment in R&D and other growth areas crucial for future success.

Past Profitability Challenges

Historical profitability issues highlight potential risks in maintaining consistent financial performance, necessitating careful management to ensure stability.

Aurinia Pharmaceuticals Business Overview & Revenue Model

Company Description

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

How the Company Makes Money

Aurinia Pharmaceuticals generates revenue primarily through the sale of its commercialized product, LUPKYNIS, which was approved by the FDA for the treatment of lupus nephritis. The company earns income from product sales to healthcare providers and patients, and it may also benefit from potential royalties and milestone payments if it enters into partnerships or collaborations with larger pharmaceutical companies for further development and commercialization of its pipeline products. Additionally, Aurinia may receive funding through research grants or government programs aimed at supporting innovative drug development in the healthcare sector.

Aurinia Pharmaceuticals Financial Statement Overview

Summary

Aurinia Pharmaceuticals is on a positive financial trajectory, marked by strong revenue growth, improved profitability, and effective cash flow management. The solid equity position and conservative leverage enhance financial stability. While past challenges in profitability and cash flow variability are noted, the recent financial performance suggests the company is well-positioned for future growth. Continued attention to capital management and operational efficiency will be key to sustaining this momentum.

Income Statement

Aurinia Pharmaceuticals has demonstrated impressive revenue growth and profitability improvement. The TTM (Trailing-Twelve-Months) data shows a significant increase in total revenue by 10.63% compared to the previous year. Net profit margin improved substantially from the previous negative figures to a positive 23.31%. Both EBIT and EBITDA margins are strong at 20.00% and 30.15%, respectively, reflecting effective cost management and operational efficiency. However, the company previously faced some profitability challenges which are important to monitor.

Balance Sheet

The balance sheet reflects a solid equity position with an equity ratio of 66.70%, indicating financial stability. The debt-to-equity ratio stands at 0.24, suggesting conservative leverage and a manageable debt load. Return on equity has improved to 18.08%, showing enhanced shareholder value creation. However, a reduction in stockholders' equity suggests a need for careful capital management moving forward.

Cash Flow

Aurinia Pharmaceuticals shows strong cash flow management with a notable increase in free cash flow, growing by 109.41% year-over-year. The operating cash flow to net income ratio is 1.53, indicating efficient conversion of earnings into cash. Free cash flow to net income ratio is also robust at 1.52, reflecting the company’s strong cash-generating ability. Nevertheless, past periods show some variability in cash flow performance.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	260.11M	235.13M	175.51M	134.03M	45.60M	50.12M
Gross Profit	232.84M	206.88M	161.37M	128.37M	44.51M	-209.00K
EBITDA	86.50M	31.73M	-63.05M	-103.65M	-177.44M	-102.92M
Net Income	60.64M	5.75M	-78.02M	-108.18M	-180.97M	-102.68M
Balance Sheet
Total Assets	502.56M	550.64M	548.06M	470.86M	543.37M	463.66M
Cash, Cash Equivalents and Short-Term Investments	315.13M	358.48M	350.49M	389.39M	466.08M	398.33M
Total Debt	81.83M	79.37M	97.61M	8.09M	8.74M	8.41M
Total Liabilities	167.26M	173.17M	170.11M	65.42M	64.28M	55.91M
Stockholders Equity	335.30M	377.48M	377.95M	405.44M	479.09M	407.75M
Cash Flow
Free Cash Flow	92.38M	44.11M	-34.18M	-79.82M	-159.19M	-77.20M
Operating Cash Flow	92.66M	44.39M	-33.46M	-79.53M	-157.69M	-69.86M
Investing Cash Flow	46.41M	39.26M	-6.71M	-60.63M	-103.87M	-158.19M
Financing Cash Flow	-119.50M	-49.09M	-5.13M	2.43M	221.11M	194.38M

Aurinia Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 12.85
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUPH, the sentiment is Positive. The current price of 12.85 is above the 20-day moving average (MA) of 12.48, above the 50-day MA of 11.38, and above the 200-day MA of 9.01, indicating a bullish trend. The MACD of 0.42 indicates Positive momentum. The RSI at 62.30 is Neutral, neither overbought nor oversold. The STOCH value of 64.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AUPH.

Aurinia Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUPH	79 Outperform	$1.70B	30.12	17.33%	―	25.59%	―
ARDX	59 Neutral	1.48B	-25.22	-40.41%	―	83.88%	15.24%
OCUL	56 Neutral	2.19B	-9.58	-70.85%	―	-7.26%	-15.33%
LQDA	52 Neutral	1.89B	-13.32	-168.74%	―	30.20%	-7.22%
CLDX	50 Neutral	1.70B	-8.39	-30.46%	―	-30.25%	-9.70%
IOVA	46 Neutral	767.13M	-1.65	-55.82%	―	636.99%	27.10%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Aurinia Pharmaceuticals Corporate Events

Aurinia Pharmaceuticals Approves New Equity Incentive Plan

At the annual general meeting held on May 15, 2025, Aurinia Pharmaceuticals‘ shareholders approved an amended Equity Incentive Plan and revised Bylaws allowing shareholders to set the number of directors. The meeting also resulted in the election of several board members and the approval of PricewaterhouseCoopers LLP as the company’s independent accounting firm. These changes are expected to enhance corporate governance and align executive compensation with shareholder interests.

The most recent analyst rating on (AUPH) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.